Merck KGaA first quarter earnings grows on higher volumes, margins
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
The company exports mobile surgery equipment to over 100 countries from Pune
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company also raised Rs 270 crore investment from Temasek in 2019
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Subscribe To Our Newsletter & Stay Updated